| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA672: Brolucizumab for treating wet age-related macular degeneration |
|
Medicine details |
|
| Medicine name | brolucizumab (Beovu®) |
| Formulation | intravitreal injection |
| Reference number | 2987 |
| Indication | Treatment of neovascular (wet) age-related macular degeneration (AMD) |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Eye |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/01/2020 |
| NICE guidance | TA672: Brolucizumab for treating wet age-related macular degeneration |